Precision Nanomedicine for Cancer: Innovations, Strategies, and Translational Challenges.

As nanotechnology advances rapidly, it has propelled nanomedicine into a revolutionary frontier for anticancer therapy. This review comprehensively analyzes the core principles, key innovations, and strategic approaches driving the development of targeted nanotherapeutics against tumors. We elucidate the distinctive properties of nanoscale drug delivery systems (eg, liposomes, polymeric nanoparticles, inorganic nanoparticles, and hybrid systems) and their capacity to be designed to surmount the constraints of traditional cancer treatments by potentially augmenting drug specificity, bioavailability, and minimizing systemic toxicity, with some nanocarriers (eg, liposomal doxorubicin) already approved for clinical use. With a focus on both the enhanced permeability and retention (EPR) effect-mediated passive targeting and ligand-based active targeting mechanisms employing peptides, aptamers, and antibodies, we investigate how these nanocarriers are engineered for efficient tumor-targeted drug delivery. The review further delves into the understanding of nano-bio interactions (eg, size-dependent cellular uptake) and their interplay with cancer biology. We discuss how this knowledge, alongside the rational design of stimuli-responsive and multifunctional "smart" nanoplatforms, informs the development of more precise and effective therapeutic strategies. Finally, we address the ongoing challenges in clinical translation, such as patient heterogeneity and physiological barriers, and emphasize that comprehending these aspects is pivotal for guiding future translational research towards the realization of truly patient-centric nanomedicines.